These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 24226152)

  • 21. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
    Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
    Lincz LF; Lonergan A; Scorgie FE; Rowlings P; Gibson R; Lawrie A; Seldon M
    Pathophysiol Haemost Thromb; 2006; 35(6):435-9. PubMed ID: 17565236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism.
    Coen D; Zadro R; Honović L; Banfić L; Stavljenić Rukavina A
    Croat Med J; 2001 Aug; 42(4):488-92. PubMed ID: 11471205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of factor V HR2 on thrombin generation and clinical manifestation in rare bleeding disorders.
    Strey RF; Siegemund A; Siegemund T; Schubert C; Schuster G; Wulff K; Herrmann FH
    Pathophysiol Haemost Thromb; 2005; 34(6):279-83. PubMed ID: 16772740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
    Marchetti M; Castoldi E; Spronk HM; van Oerle R; Balducci D; Barbui T; Rosing J; Ten Cate H; Falanga A
    Blood; 2008 Nov; 112(10):4061-8. PubMed ID: 18768782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case control study of deep venous thrombosis in relation to factor V G1691A (Leiden) and A4070G (HR2 Haplotype) polymorphisms.
    Bouaziz-Borgi L; Nguyen P; Hezard N; Musharrafieh U; Almawi WY; Mahjoub T
    Exp Mol Pathol; 2007 Dec; 83(3):480-3. PubMed ID: 17555744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of placenta-mediated pregnancy complications or pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation.
    Cordoba I; Pegenaute C; González-López TJ; Chillon C; Sarasquete ME; Martin-Herrero F; Guerrero C; Cabrero M; Garcia Sanchez MH; Pabon P; Lozano FS; Gonzalez M; Alberca I; González-Porras JR
    Eur J Haematol; 2012 Sep; 89(3):250-5. PubMed ID: 22642978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers.
    Rühl H; Berens C; Winterhagen FI; Reda S; Müller J; Oldenburg J; Pötzsch B
    Circ Res; 2019 Aug; 125(5):523-534. PubMed ID: 31314700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of activated protein C resistance, factor V coagulation activity and gene polymorphisms in patients with venous thromboembolism].
    Han XM; Ren JF; Hao B; Cao WD; Liu XE; Hou LH; Guo ZP; Yu B; Wang XF; Ding QL; Yang LH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):612-6. PubMed ID: 17605877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prothrombin A19911G polymorphism and the risk of venous thromboembolism.
    Martinelli I; Battaglioli T; Tosetto A; Legnani C; Sottile L; Ghiotto R; Mannucci PM
    J Thromb Haemost; 2006 Dec; 4(12):2582-6. PubMed ID: 16981886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of common genetic variations and idiopathic venous thromboembolism. Results from EDITh, a hospital-based case-control study.
    Delluc A; Gourhant L; Lacut K; Mercier B; Audrezet MP; Nowak E; Oger E; Leroyer C; Mottier D; Le Gal G; Couturaud F
    Thromb Haemost; 2010 Jun; 103(6):1161-9. PubMed ID: 20352152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
    Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
    J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association of idiopathic recurrent pregnancy loss with polymorphisms in hemostasis-related genes.
    Cao Y; Zhang Z; Xu J; Yuan W; Wang J; Huang X; Shen Y; Du J
    Gene; 2013 Nov; 530(2):248-52. PubMed ID: 23954867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
    Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
    Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation.
    Tosetto A; Rodeghiero F; Martinelli I; De Stefano V; Missiaglia E; Chiusolo P; Mannucci PM
    Br J Haematol; 1998 Dec; 103(3):871-6. PubMed ID: 9858248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of inherited thrombophilia: guide for genetics professionals.
    Varga EA; Kujovich JL
    Clin Genet; 2012 Jan; 81(1):7-17. PubMed ID: 21707594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type and location of venous thromboembolism in carriers of Factor V Leiden or prothrombin G20210A mutation versus patients with no mutation.
    Kovac M; Mitic G; Mikovic Z; Antonijevic N; Djordjevic V; Mikovic D; Mandic V; Rakicevic L; Radojkovic D
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):66-70. PubMed ID: 18796457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
    Libourel EJ; Bank I; Meinardi JR; Baljé -Volkers CP; Hamulyak K; Middeldorp S; Koopman MM; van Pampus EC; Prins MH; Büller HR; van der Meer J
    Haematologica; 2002 Oct; 87(10):1068-73. PubMed ID: 12368162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden.
    Lincz LF; Adams MJ; Scorgie FE; Thom J; Baker RI; Seldon M
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):559-64. PubMed ID: 17762532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.